Medical Digest & Congress Report

Professor Renata Cifkova was responsible in the new ESH Hypertension guideline for the topic of hypertension in women. In the interview, she explained what clinicians should know about this important topic. Video: https://medicaldigest.org/scientific-contents/interview:hypertension-women-underrecognized-issue

Professor Bryan Williams was the driving force behind the 2018 ESH/ESC Hypertension guideline. Many points - including the algorithm for drug therapy - represented a significant step forward for practicing physicians. What changes have been made in the recently presented and published guideline concerning the diagnosis of hypertension and its diagnostic possibilities? Have there been any changes i...

Dr. Vitoria Cunha explains what is the relationship and effect of hypertension and dyslipidemia on each other? Is it recommended to treat the two risk factors together? How could the combined treatment of the two risk factors be made more accepted and routine among treating physicians? From the perspective of patients, how is it appropriate to communicate the global cardiovascular risk factor mana...

Professor Konstantinos Tsioufis highlights an important aspect of the new ESH Hypertension guideline: hypertension and cardiac diseases. How these are connected to each other? How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment? Video: https://medicaldigest.org/scientific-contents/interview:hypertensive-patients-heart-disease-what-should-be-preferred-...

Professor Reinhold Kreutz shares his insights about the antihypertensive triple fixed combinations. What pathophysiological bases justify the use of triple fixed combinations? How does the newly published guidelines determine the place of triple fixed combinations? Video: https://medicaldigest.org/scientific-contents/interview:where-role-triple-combination-management-hypertension

Professor Neil Poulter share his insights on the development of guidelines and the treatment in general in the last 15 years, and the practical application of new guidelines. Video: https://medicaldigest.org/scientific-contents/interview:development-hypertension-guidelines

Professor Krzysztof Narkiewicz Explains his Take on Single Pill Combination Treatment in Hypertension. Video: https://medicaldigest.org/scientific-contents/interview:ten-commandments-single-pill-combination-treatment-hypertension

Professor Felix Mahfoud explains the place of beta-blockers in the new ESH guideline, and in combination he recommends them even in the first line. Video: https://medicaldigest.org/scientific-contents/interview:beta-blockers-managing-arterial-hypertension-why-when-and-whom

Professor Martin Strauss explains the preferred treatment of hypertension with a preferred RAAS blockade inhibitors. What kind of pill combination to choose? Video: https://medicaldigest.org/scientific-contents/interview:beyond-algorithm-what-combination-choose-hypertension-treatment

Professor Michel Burnier presented the general aspects of the new European Society of Hypertension guidelines at ESH 2023. What are the major changes? Video: https://medicaldigest.org/scientific-contents/interview:antihypertensive-drugs-and-treatment-algorithms-esh2023-hypertension-guidelines

Professor Pantelis Sarafidis shared his insights on kidney disease and hypertension, and what the new ESH guidelines said about the management the hypertension people with chronic kidney disease. Video: https://medicaldigest.org/scientific-contents/interview:hypertension-and-kidney-intricate-relationship

Professor Paolo Palatini chaired a very interesting session at the ESH 2023 about the hot questions on blood pressure measurement. - How to best perform office blood pressure management? - How to measure blood pressure in the very obese patients? - Should ABPM parameters have a role in clinical practice? - How to manage masked and masked uncontrolled hypertension? - How to manage isolated systolic...

Professor Frederick Raal about an interim analysis of a phase 2 study demonstrates that the RNAi therapeutic ARO-ANG3 reduces LDL-c and ApoB in patients with homozygous familial hypercholesterolaemia. Video: https://medicaldigest.org/scientific-contents/interview:significant-ldl-cholesterol-reductions-angptl3-sirna-homozygous-familial-hypercholesterolaemia

Professor Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain explains the HER2 treatment landscape in 2023. The interview answers the following questions: 1. HER2-targeting antibody-drug conjugates, T-DM1 and T-DXd have remarkably improved overall survival in patients with HER2-positive mBC. Why do these modern ADCs work so well, what makes them different from previo...

Professor Amany Elshorbagy explains, that obese children and adults with heterozygous familial hypercholesterolemia have a higher risk of coronary artery disease compared with HeFH patients with normal weight. A similar trend is observed in patients with homozygous FH. These are the findings of a cross-sectional analysis on 35,919 patients from 46 countries of the EAS FH Studies Collaboration Regi...

Dr. Maksym Breslavets, Medical Director of Centre for Medical and Surgical Dermatology in Canada explains how artificial intelligence application may play an essential role in clinical dermatology and has previously been evaluated to identify malignant skin lesions and assist with triage of psoriasis patients. For more information: https://www.jaad.org/article/S0190-9622(21)00220-6/fulltext Interv...

Prof. Matteo Lambertini explains the highlights of the 2023 ESMO Breast Cancer Conference. - There are more insights of the toxicity of the new ACD's, paticullary for trastuzumab deruxtecan. Updated data on the DESTINY (DESTINY-Breast04, 02) trials in the terms of toxicities. - CAPItello-291, capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with horm...

We asked Professor Paolo Ascierto, world known expert in the field of skin cancer treatment about hot topics in melanoma management. Based on the current evidence, clinical trial data and real world data, what seems to be the best sequence? Open questions include topics in melanoma management the need of adjuvant treatment for high risk pts. What are the pros and cons of adjuvant therapy? Is it st...

Professor Anthony Letai, President of the Society for Functional Precision Medicine explains the concept of functional precision medicine in oncology: we take the patient's living tissue and expose it to drugs, then ask if there is an effect, we can measure that predicts response in vivo. Dr. Letai is convinced that this will be a valuable diagnostic tool, the next step in precision medicine....

Jeffrey Weber explains the efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial presented at ACCR 2023. The personalized mRNA-based cancer vaccine plus pembrolizumab demonstrated efficacy in the adjuvant setting for patients with resected high-risk melanoma. It is the first - randomized trial that shows benefit for a neoantigen vaccine approach of an...

Professor Istvan Bitter from Semmelweis University, Budapest, Hungary is sharing his insights on schizophrenia treatment. In the last decades numerous second generation antipsychotics have been introduced. Considering efficacy and safety profiles, how can we personalize treatment? What is the treatment approach for patients with predominant negative symptoms? People with schizophrenia often die pr...

Professor Peter Falkai, past president of the European Psychiatric Association, is sharing his insights on the EPA 2023 Congress, guided by the motto “Social Cohesion, a Common Goal for Psychiatry”. He discussed topics such as the role of loneliness in the development of mental illnesses, the impact of nutrition in the development and prevention of mental illness, as well as the most important nov...

Prosessor Eliot A. Brinton on the risk and incidence of recurrent CV events post-AMI, and the role of cholesterol efflux and ApoA-I in plaque stabilization. There is a large clinical trial ongoing, that have results in the next 1-2 years. Let's keep tuned to this study and see what we see in the near future. Video: https://medicaldigest.org/scientific-contents/interview:risk-early-recurrent-mi...

Prosessor Eliot A. Brinton explains the results of the CLEAR Outcomes trial, the first study to assess whether bempedoic acid could reduce cardiovascular outcomes. The cholesterol-lowering drug bempedoic acid reduced the combined rate of major adverse cardiovascular events by 13%, meeting its primary endpoint in a large study of patients with high cholesterol who were unable to tolerate statins, a...

Dr. Neha Pagidipati presented the COORDINATE-Diabetes Study's primary results. Evidence-based therapies are under-used in clinical practice, and there is little high-quality data on how to improve this. This multifaceted intervention is effective in increasing the prescription of evidence-based therapies in adults with T2D and ASCVD. For more information visit: coordinatediabetes.org Video: ht...